<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03885180</url>
  </required_header>
  <id_info>
    <org_study_id>2019-P-026</org_study_id>
    <nct_id>NCT03885180</nct_id>
  </id_info>
  <brief_title>Randomized Evaluation of D-dimer Guiding dUration of Oral antiCoagulation thErapy</brief_title>
  <acronym>REDUCE</acronym>
  <official_title>Randomized Evaluation of D-dimer Guiding Duration of Oral Anticoagulation Therapy in Patients With Bioprosthetic Heart Valves</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Asia Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Asia Heart Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Guidelines recommended that patients with bioprosthetic heart valves (BHV) only need 6 months
      oral anticoagulation therapy after operation. However, a small part of patients still
      suffered thrombotic events after withdrawal of warfarin, which means these patients may need
      extend anticoagulation therapy. D-dimer, a sensitive marker of thrombosis or
      prethromboembolism state. Previous studies have demostrated that patients with elevated
      D-dimer levels have significant more clinical outcomes than those with nagative D-dimer
      levels. The aim of this study was to evaluate whether D-dimer could guide the duration of
      oral anticoagulation therapy in patients with BHV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with BHV were screened and enrolled in this study. D-dimer levels were measured in
      the sixth months after BHV operation but before withdrawal of warfarin. Patients with
      elevated D-dimer were randomized to extend anticoagulation therapy group and routine stopping
      anticoagulation group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombotic events</measure>
    <time_frame>24 months</time_frame>
    <description>Stroke, DVT, PE, valve thrombosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Valve Heart Disease</condition>
  <condition>Anticoagulants; Increased</condition>
  <arm_group>
    <arm_group_label>Extend anticoagulation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extended the duration anticoauglation to 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stop anticoagulation group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Just stop oral anticoagulation like routine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin Sodium</intervention_name>
    <description>Extending warfarin anticoagulation</description>
    <arm_group_label>Extend anticoagulation group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients received BHV within 3 months

        Exclusion Criteria:

          -  Recently throboemblism within 6 months

          -  Recently bleedings within 3 months

          -  Evaluated lifetime less than 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Wuhan Asia Heart Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhang li tao, MD.P</last_name>
      <phone>+86 02765796739</phone>
      <email>zhangleetau@163.com</email>
    </contact>
    <investigator>
      <last_name>zhang li tao, MD.P</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>March 24, 2019</last_update_submitted>
  <last_update_submitted_qc>March 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan Asia Heart Hospital</investigator_affiliation>
    <investigator_full_name>Litao Zhang, MD</investigator_full_name>
    <investigator_title>Head of anticoagulation clinic</investigator_title>
  </responsible_party>
  <keyword>bioprosthetic heart valves</keyword>
  <keyword>oral anticoagulation</keyword>
  <keyword>thrombotic events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

